Press Releases about Travere Therapeutics Inc
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
Via GlobeNewswire
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
Via GlobeNewswire
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
Via GlobeNewswire
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
Travere Therapeutics Announces Proposed Public Offering of Common Stock
February 27, 2023
Via GlobeNewswire
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
![](https://mms.businesswire.com/media/20230217005377/en/346436/5/Ligand-Logo-Registered5.jpg)
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
Travere Therapeutics to Present at Upcoming Investor Conferences
February 08, 2023
Via GlobeNewswire
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
Travere Therapeutics Provides Corporate Update and 2023 Outlook
January 09, 2023
Via GlobeNewswire
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
Travere Therapeutics to Present at Upcoming Investor Conferences
November 09, 2022
Via GlobeNewswire
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
Travere Therapeutics Reports Third Quarter 2022 Financial Results
October 27, 2022
Via GlobeNewswire
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
Travere Therapeutics to Report Third Quarter 2022 Financial Results
October 20, 2022
Via GlobeNewswire
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
![](https://ml.globenewswire.com/media/e7252f5a-bd9e-4e33-9eb0-153976c06a3f/small/travere-txtm-inline-fullcolor-png.png)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.